Viridian Therapeutics Inc
General ticker "VRDN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B
Viridian Therapeutics Inc follows the US Stock Market performance with the rate: 25.0%.
Estimated limits based on current volatility of 5.8%: low 18.22$, high 20.48$
Factors to consider:
- Current price 18.4% above estimated high
- Earnings for 18 months up through Q2 (+1 year) are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [10.60$, 26.15$]
- 2023-12-31 to 2024-12-30 estimated range: [6.24$, 16.61$]
Financial Metrics affecting the VRDN estimates:
- Negative: Non-GAAP EPS, $ of -4.03 <= 0.10
- Negative: Operating profit margin, % of -98.70 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -9.80 <= 2.35
- Negative: Industry earnings per price (median), % of -24.66 <= 1.31
- Negative: Inventory ratio change, % of 87.03 > 1.08
- Negative: Investing cash flow per share, $ of -3.59 <= -3.48
- Negative: Industry operating cash flow per share per price (median), % of -21.66 <= 3.85
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term VRDN quotes
Long-term VRDN plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $2.96MM | $1.77MM | $0.31MM |
| Operating Expenses | $82.69MM | $136.08MM | $254.76MM |
| Operating Income | $-79.73MM | $-134.30MM | $-254.45MM |
| Non-Operating Income | $0.32MM | $4.43MM | $16.72MM |
| Interest Expense | $0.00MM | $0.49MM | $1.85MM |
| R&D Expense | $56.89MM | $100.89MM | $159.76MM |
| Income(Loss) | $-79.41MM | $-129.87MM | $-237.73MM |
| Profit(Loss) | $-79.41MM | $-129.87MM | $-237.73MM |
| Stockholders Equity | $187.72MM | $395.06MM | $442.02MM |
| Inventory | $0.00MM | $6.62MM | $0.00MM |
| Assets | $203.71MM | $435.09MM | $490.42MM |
| Operating Cash Flow | $-54.58MM | $-93.84MM | $-184.17MM |
| Capital expenditure | $0.34MM | $0.80MM | $0.90MM |
| Investing Cash Flow | $-74.29MM | $-115.13MM | $-94.25MM |
| Financing Cash Flow | $125.28MM | $322.24MM | $225.67MM |
| Earnings Per Share* | $-6.66 | $-3.91 | $-5.31 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.